Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nefecon + ambrisentan
- Development stage
- Unknown
- Lead developer
- Calliditas Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nefecon + ambrisentan is a combination therapy under clinical investigation for the treatment of **IgA nephropathy (IgAN)**. Nefecon is an oral, targeted-release formulation of the corticosteroid budesonide, specifically engineered to deliver budesonide to the distal ileum where mucosal immune responses driving IgAN are concentrated. It exerts anti-inflammatory and immunosuppressive effects by activating glucocorticoid receptors, dampening the production of pathogenic IgA. Ambrisentan is a selective endothelin type A receptor antagonist, primarily approved for pulmonary arterial hypertension, which blocks endothelin-mediated vasoconstriction and inflammation. This combination is being evaluated for potential synergy in reducing proteinuria and slowing kidney function decline in IgAN patients by targeting different but complementary pathogenic mechanisms: immune modulation at the gut level and inhibition of endothelin-driven renal injury.[1][2][3][4][5][8]
- Brand names
- Ambrisentan Mylan
- Other names
- targeted-release budesonide + ambrisentan
02
Targets
GR (Glucocorticoid receptor)EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on Nefecon + ambrisentan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nefecon + ambrisentan.